Abrocitinib improved symptoms and disease impacts in adults with moderate to severe atopic dermatitis (AD), according to results from a phase 2b study published in Dermatitis.
“The aim of the study was to evaluate patient-reported outcomes in a phase 2b study of abrocitinib in adults with moderate to severe AD inadequately controlled by topical therapy (NCT02780167),” explained the study authors.
Researchers randomly assigned patients to 12-week, once-daily abrocitinib (200, 100, 30, or 10 mg) or placebo. Patient-reported outcomes included pruritus numeric rating scale (average), Patient Global Assessment (PGA), Patient-Oriented Eczema Measure (POEM), Pruritus and Symptoms Assessment for AD (PSAAD), Dermatology Life Quality Index (DLQI), and Hospital Anxiety and Depression Scale (HADS).
The 200 or 100 mg dose of abrocitinib resulted in greater improvements from baseline compared with placebo. Improvements with abrocitinib were shown in peak pruritus numeric rating scale (by days 2 and 3, respectively), POEM, PSAAD, DLQI, and HADS (200 mg only, by week 1 or 2), and proportions of the patients with PGA clear/almost clear with 2-point or greater improvement (by weeks 1 and 4, respectively) that continued through week 12 (except HADS).
“Abrocitinib treatment resulted in rapid (2 days to 2 weeks) and persistent improvements in AD symptoms and impacts in moderate-to-severe disease,” concluded the study authors. –Lisa Kuhns
Reference
Simpson EL, Wollenberg A, Bissonnette R, et al. Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis. Published on March 31, 2021. doi:10.1097/DER.0000000000000725
